Global regulators call for advancing alternatives to animal testing across the medicine lifecycle

Imported from official source

Announcement

Safety Classified by Officially

EMA has endorsed a joint statement from the International Coalition of Medicines Regulatory Authorities (ICMRA) calling on medicine developers, manufacturers, regulators and national control laboratories to continue to advance and implement alternative methods or approaches to animal testing throughout the lifecycle of human medicines, wherever, and as soon as possible.

EMA has a longstanding commitment to the 3Rs principles – to replace, reduce and refine the use of animals in medicines development and regulation. Because medicines are developed and regulated in a global environment, meaningful progress in reducing animal use depends on the worldwide development and regulatory acceptance of scientifically valid, 3Rs-compliant approaches. Promoting international alignment and harmonisation of regulatory approaches through ICMRA are central to this effort.

The development of the joint statement was led by EMA, the UK Medicines and Healthcare products Regulatory Agency (MHRA), the Irish Health Products Regulatory Authority (HPRA) and Swissmedic, the Swiss Agency for Therapeutic products. Adopted by the ICMRA plenary, the statement sets out the long-term goal of replacing animal testing throughout all stages of a medicine’s lifecycle: from initial candidate screening and early development, through pre-clinical and non-clinical testing to licensing and post-authorisation activities. Achieving this will require a cautious and stepwise transition to non-animal methods that are scientifically valid and acceptable for regulatory authorities, supported by robust evidence and open global interaction between regulators, medicine developers and innovators of alternative approaches.

For new medicines, from development to authorisation, ICMRA calls on:

  • medicine developers globally to employ methods that do not involve the use of animals and that are acceptable in a regulatory context while safeguarding scientific quality;
  • This is an extract. The publication continues at the source.

    Source: European Medicines Agency.

    Read the original at the source: https://www.ema.europa.eu/en/news/global-regulators-call-advancing-alternatives-animal-testing-across-medicine-lifecycle This address stopped responding when last checked on November 17, 2026. The record below is what Officially captured.

    Officially imported this from European Medicines Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

    Provenance

    Organization
    European Medicines Agency — imported from official source
    Official source
    https://www.ema.europa.eu/en/news.xml RSS
    Imported
    October 03, 2026 20:30
    Versions
    1 recorded
    Identity
    https://www.ema.europa.eu/en/news/global-regulators-call-advancing-alternatives-animal-...

    Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.